Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Best Buy" NSAID Rxs Up Since Vioxx Withdrawal, But Mobic Growing Faster, Consumers Union Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Prescriptions for Abbott/Boehringer Ingelheim's Mobic doubled from September to March and the average retail price rose 9% in the same period, Consumers Union notes. Scripts for ibuprofen were up 28%, but prices were "relatively flat," the report says.

You may also be interested in...



Mobic Generic Competition Possible In Early 2006

Boehringer Ingelheim brand rings up $293 mil. in first quarter sales as biggest beneficiary from COX-2 safety issues. Mobic loses exclusivity April 13, although generics are unlikely to enter the market for at least nine months.

Abbott/Boehringer's Mobic Sales Surge On COX-2 Safety Concerns

Sales of the non-steroidal anti-inflammatory agent jumped 177% in the fourth quarter on the heels of Merck's withdrawal of Vioxx. Abbott expects sales of Mobic to reach $1 bil. in 2005. The levothyroxine brand Synthroid is retaining 70% of the share it held before entry of generic competition.

Lipitor, Lovastatin Are “Best Buy” Statins, Consumers Union Says

Pfizer’s statin is rated the best value for patients needing to reduce LDL cholesterol more than 40%, but generic lovastatin is best for patients needing a smaller reduction. Consumer Reports publisher posts drug comparison reports for statins, NSAIDs and PPIs on its website.

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel